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Although stavudine and zidovudine remain frequently used in low-income countries in Africa, they are associated with long-term
toxicities. Lactic acidosis is one of the most serious toxicities in antiretroviral treatment (ART) and occurs predominantly in
regimens containing stavudine (D4T) or zidovudine (AZT). We conducted this study to determine the incidence and risk factors
for lactic acidosis among HIV-positive patients that have been on ART for at least 6 months. This study will bridge the gap that
exists due to scarcity of data on the extent of toxicities due to long-term use of D4T and AZT. We conducted a retrospective
cohort study using routine clinic data from the Lighthouse and Martin Preuss Centre electronic data systems. We used the clinic
data collected between 1st January 2004 and 31st December 2011. We included into the analysis all patients that have been on
D4T- or AZT-containing ARVdrugs for at least 6 months.We analysed the data using Poisson regression of the number of cases of
lactic acidosis (LA) on gender, age at ART initiation, baseline BMI, and lipodystrophy in order to determine the incidence and risk
factors for lactic acidosis. All statistical analyses were done at 5% significance level.We identified 14,854 patients that have ever
been on D4T- or AZT-containing ARVdrugs for longer than 5 months. Of these, 43% were male and median age was 34 years.The
total number of cases of confirmed LA was 342 with observed mortality rate 40% more than the patients without confirmed LA.
There were 23.02 cases of LA for every 1000 patient-years on D4T- or AZT-containing ART regimens. The strongest risk factor
identified for developing LA was having a baseline BMI  25 with incidence rate ratio (IRR) 3.11 (95% CI: 2.49, 3.88).The IRR for
patients with a diagnosis of lipodystrophy was 1.77 (95% CI: 1.35, 2.32). Patients aged B30 years at ART initiation had 31%
reduced risk of developing LA as compared to patients aged 39 years at ART initiation.We were unable to detect any increased
risk associated with gender. Clinicians should always have significantly higher index of suspicion of LA in patients with
established lipodystrophy, aged more than 30 years at ART initiation and patients with higher baseline BMIs. The number of
cases of fatal lactic acidosis that did not present to the clinic is unknown but is likely to be significant.
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